Altoida, Inc is creating a new gold standard in brain health with Precision Neurology. Their innovative approach combines novel digital biomarkers (dBM) with immersive augmented reality (AR) and powerful artificial intelligence (AI). The result is a validated device and platform built on more than twenty years of cutting-edge scientific research. Altoida’s products are backed by peer-reviewed publications and multinational clinical trials, and are built by their expert team of scientists, clinicians and engineers.
Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. Antonella Santuccione Chadha as Chief Medical Officer. In this new role, Dr. Chadha will lead all clinical and medical affairs as the company continues to develop, validate, and commercialize its AI-driven digital biomarker platform. She will report directly to the Chief Executive Officer of Altoida, Travis Bond, and will serve on the Leadership team.
2022/03/30Altoida, Inc. raised an additional $14 million for its Series A round with new and existing investors. The investment was co-led by M Ventures and Whitecap Venture Partners
2021/10/18Research collaboration will identify new opportunities in the fight against Alzheimer’s and further validate the predictive diagnostic capabilities of Altoida’s software medical device.
Refreshed brand identity reflects Altoida’s emphasis on data and humanity, and will support the company’s growth as the world leader in Precision Neurology
Breakthrough Designation will advance the development of industry’s first predictive diagnostic device for conversion to Alzheimer’s disease, backed by two decades of global clinical studies
New digital biomarkers company secures $6.3 MM in venture capital to detect Alzheimer’s disease 6-10 years prior to onset of Mild Cognitive Impairment (MCI) symptoms - with up to 94% accuracy
